Gilead's Biktarvy Patent Extended to 2036
Gilead Sciences settled lawsuits with generic manufacturers, securing market exclusivity for Biktarvy until April 2036.
Already have an account? Sign in.
Gilead Sciences settled lawsuits with generic manufacturers, securing market exclusivity for Biktarvy until April 2036.
JPMorgan upgrades Camp4 to Overweight, sees strong upside from CMP-002, with trials planned in 2026 and promising early results.
Dave & Buster’s Q1 2026 revenue and profit fell, missed forecasts, but management expects recovery and stronger cash flow ahead.
Qualcomm is in early talks to buy Jim Keller’s Tenstorrent to expand its AI chip capabilities and challenge Nvidia in data center and edge AI. Intel is also interested.